Ji‐Youn Han

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

Ji‐Youn Han, Dae Ho Lee, Hae Young Kim et al. · Cancer · 2003 · 30 citations · Full text

DNA repair gene polymorphisms and benefit from gefitinib in never‐smokers with lung adenocarcinoma

Ji‐Youn Han, Kyong‐Ah Yoon, Jae Hee Park et al. · Cancer · 2011 · 23 citations

Genetics, Lung Adenocarcinoma, Genetic Epidemiology +17

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Helena A. Yu, Myung‐Ju Ahn, Sang‐We Kim et al. · Cancer Research · 2019 · 21 citations

Met-amplified Nsclc, Metastatic Nsclc, Pathology +16

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Sreenivasa R Chandana, Noura J. Choudhury, Afshin Dowlati et al. · Journal of Clinical Oncology · 2024 · 21 citations

Sez6 Expression, Immunology, First-in-human Study +21

Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report

Alexander I. Spira, Luis Paz‐Ares, Ji‐Youn Han et al. · Journal of Thoracic Oncology · 2025 · 20 citations · Full text